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positive. Symptoms were night svveats only. Blood cultures
remained sterile.
Patients l and 2 were treated with 200 mg doxycycline
daily for 6 vveeks with intra-muscular netromycin (150
mg/day) for 2 weeks. Patient 3 was treated with trimethoprim
160 mg-sulfamethoxazole 800 mg tablets twice daily for 10
days because of her pregnancy. Therapeutic abortion was
done after 9 days of treatment because of the risk of vertical
transmission. Treatment with rifampicin 600 mg/day and
doxycycline 200 mg/day was started. Symptoms disappeared
after 4 weeks. Placental cultures were negative.
This laboratory epidemic confirms the Professional risk
involved in sniffing cultures, a habit common in French
laboratories to guide bacterial identification. Delays in
seroconversion for two patients indicate that serum
surveillance must be for at least 3 months. The index case is
atypical, which shows that systematic precautions must be
taken whatever the origin of the samples. For patient 3, the
mother-to-fetus transmission is unknown, and a large
number of cases would have to be followed to allow a
conclusion.3
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Oral anticoagulants and fetal loss
SIR—The EPCOT study group (Oct 5, p 913)' show a
relation between fetal loss and inherited thrombophilic
defects. The mechanism of impaired placental development
and function would certainly be a logical mechanism for the
increased fetal loss recorded. However, another factor in fetal
outcome was not addressed—namely, the effect of
anticoagulation during pregnancy. The investigators do not
mention whether any patients received anticoagulants during
pregnancy, and if they did, which anticoagulant was used?
Since the index group contained individuals with Symptoms
it would be presumed that some would have received such
anticoagulation, and that the control group of healthy
individuals would not.
Oral anticoagulants seem to increase fetal and neonatal
deaths,2 whereas heparin may not have such an effect. In a
retrospective study such äs EPCOT, oral anticoagulants may
have been used in the past, despite reluctance to use them
now. Furthermore, the individuals with the highest fetal loss
(combined defects and antithrombin deficiency) in this study
are those who are likely to have more pregnancy/non-
pregnancy associated thrombotic problems3 and therefore be
candidates for therapeutic or prophylactic anticoagulation
during pregnancy, irrespective of whether the defects were
diagnosed after the pregnancies. Finally, the increased risk, if
any, is low in patients with the factor V Leiden defect; this is
a recently de-~ribed familial thrombophilic defect. Since
decisions on anticoagulation during pregnancy take into
consideration underlying thrombophilic disorders, this group
is less likely to have been considered for prophylactic
anticoagulants beforc the description of the underlying
defect.
The EPCOT rcport has raised an important issue about
fetal loss and possible therapeutic interventions to reducc this
loss. Information about the possible effects of anticoagulants
on the results presented would be helpful in the
Interpretation of the data because one can postulate that oral
anticoagulation could either increase or decrease fetal loss.
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A uthors' reply
SIR—Brown and Collins raise the interesting and valid point
that the increased fetal losses in women with heritable
thrombophilia might be influenced by losses attributable to
oral anticoagulant thromboprophylaxis during pregnancy.
Our results, which concur with those reported by Sanson et
al,' were obtained retrospectively at enrolment into the
EPCOT study. Unfortunately we do not have detailed
Information on the use of oral anticoagulants in the women
we reported. In an attempt to address the possible role of oral
anticoagulants in the observed increased fetal losses we have
reanalysed our data, confining our analysis to those 600 of
966 pregnant women who have never had a venous
thrombotic event. Since this group of women are the least
likely candidates for anticoagulation this approach should
greatly reduce the number who receive thromboprophylaxis
during pregnancy. The analysis of this group led to a small
decrease in the risk estimate but we still find a 25% excess
risk of fetal loss. We anticipate that the prospective data
arising out of the EPCOT cohort will clarify these issues.
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SlR—In response to Preston and colleagues' report of the
EPCOT study, we record three patients with resistance to
activated protein C (APC) who, after thrombosis, had
placental abruption despite thromboprophylaxis.
A 25-year-old woman presented with her first pregnancy at
6 weeks' gestation. She had a sinus thrombosis in 1991, but
there was no family history of thrombosis. APC resistance
was diagnosed (APC ratio 1.61). She was kept on low-
molecular-weight heparin prophylaxis during pregnancy
(3075 anti-factor Xa IU, nadroparin, one subcutaneous
injection daily). At 17 weeks, placental abruption occurred
and the fetus died; there was no fetal anomaly, and the
placenta was coated by blood clots and contained several
infarctions.
A 20-year-old woman (gravida 2, para 2) was admitted
because of labour at 26 weeks' gestation, and fetal distress
was identified. After a previous normal delivery she had
thrombosis of the inferior vena cava and of the common iliac
veins. Subsequently, APC resistance (APC ratio l.C>9) and
protein S deficiency (40%) was diagnosed. The patient's
father also had APC resistance. 6 months at'ter her
thrombosis she became pregnant, during which low-
molecular-wcight heparin (nadroparin) prophylaxis was
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givcn (one 6150 anti-factor Xa IU subcutaneous injection
daily). Despite cmergoncy cacsarcan section for placental
abruption, the fctus (570 g, 30 cm) died. No fetal
malformation was found. The placenta showed numerous
small foci of ischaemic necrosis.
A 27-year-old woman (gravida 4, para 2) was admitted for
uterine blecding at 31 weeks' gestation. She had had a deep
venous thrombosis Ci years earlier after a normal delivery.
The patient's sister had a stillbirth at 34 weeks. APC
resistance was shown (APC ratio 1.65). The patient was kept
on low-molecular-weight heparin prophylaxis (3075 anti-Xa
IU, nadropariil·, one subcutaneous injection daily). At
admission fetal death caused by placental abruption and
pregnancy-induced hypertension were found. After the
stillbirth subarachnoidal haemorrhage was shown in the baby
(1500 g, 44 cm) and the placental surface was coated by
blood clots. In all patients the postabortal and postpartum
courses were uneventful.
There is evidence that APC resistance in symptom-free
women might contribute to midtrimester fetal loss.2 Our
three cases indicate that APC resistance in women after
clinical presentation of thrombosis comprises fetal outcome
more severely than in symptom-free conditions because,
despite thromboprophylaxis, the resistance may result in
placental abruption, and fetal death. Nevertheless, our
experiences suggest that the dose of low-molecular-weight
heparin recommended for thromboprophylaxis should be
increased during the pregnancy of the thrombophilic patient
who has had thrombosis; this may reduce the risk to the
fetus, just äs in those mothers with antiphospholipid
antibodies who were given full-dose heparin therapy3 after
previous fetal loss.
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SIR—Data from the EPCOT study' show an increased risk of
fetal loss in women with thrombophilia, especially in those
with antithrombin deficiency or combined defects. For
carriers of factor V Leiden no evidence of an excess risk of
miscarriage was found and data on the risk of stillbirth were
inconclusive. However, no separate analysis of women with
homozygous or heterozygous factor V Leiden was
undertaken.
We have investigated 27 women homozygous for the factor
V Leiden mutations (median age 36 years, ränge 21-60).
Some were enrolled in the EPCOT study. 26 women had
had at least one venous thromboembolic event (VTE); all
had the factor V Leiden mutation, which was detected during
laboratory evaluation, one woman was symptom-free and her
factor V Leiden Status was discovered by chance. A
standardised questionnaire was completed by personal
interview at the participating centres with particular
emphasis on obstetric history. Miscarriage was defined äs
fetal loss before and including the 28th week of gestation,
and stillbirth was defined äs intrauterine death after the 2Sth
week of gestation. 18 women had been pregnant at least once
(median=2, ränge 1-6) and had in total 42 pregnancies. In
two of the pregnancies thromboprophylaxis was carried out.
Seven (17%) pregnancies ended in miscarriage (three) or
stillbirth (four), and nine (21%) in tcrmination. One
miscarriage and three stillbirths, but none of the
terminations, were followed by deep vein thrombosis (DVT);
in one woman DVT was combined with pulmonary
embolism. In two of 24 successful pregnancies without
thromboprophylaxis DVT occurred during pregnancy and
one woman had DVT after delivery.
We conclude that the risk of stillbirth in women
homozygous for factor V Leiden (l 0%) is greater than that in
healthy women, who have a prevalence of stillbirth of about
!%.'·- The risk of miscarriage was not increased. More than
half the fetal losses were followed by VTE. The prevalence of
VTE during pregnancy and after delivery in pregnancies with
successful outcome was moderately increased, but lower than
in women with heterozygous deficiency of antithrombin
protein C, or protein S, who have a pregnancy-associated
frequency of VTE of 15-51%.* Thromboprophylaxis could
be considered during pregnancy in women homozygous for
factor V Leiden to reduce the increased risk of stillbirth
and VTE.
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Drought and malaria retreat in the Sahel,
West Africa
SIR—The Sahel is a belt of dry savanna lining the southern
border of the Sahara. Since 1970, rainfall has decreased by
nearly 30% in this region with severe droughts in 1972,
1983, and 1991-92. The impact of dryness on malaria,
endemic in the Sahelian belt, has been studied in Senegal
(the Niayes) and the Niger Republic (Niger Valley, Zinder,
Diffa).
The Niayes are marshy areas, located in north-west
Senegal. Mean annual rainfall decreased from 684 mm
(1931-60) to 427 mm (1980-89), and to 259 mm (1992)
(figure). The rainy season shortened from 6 to 4 months.
The same was observed in Niger, where the rainfall at
Niamey decreased from 640 mm (1950-69) to 457 mm
(1981-90). The environment has changed drastically under
the combined impact of drought and population growth.
Numerous trees were cut for domestic use and stayed
unreplaced due to the drought. In Niger and Senegal,
marshes with emergent Vegetation (cattail) were larval
habitats of Anophdes funestus, a major malaria vector. Then,
these habitats became dry even after the rainy season,
although their soil retained some moisture allowing
vegetable cultivation. As a consequence of environmental
changes this vector almost disappeared, comparing data
recorded before 1970 and after 1988. In Senegal, An funestus
accounted for 66% of night-landing collections in 1967 with
an average of 33 bites per man per night and a sporozoitic
index between 1-2 and 3-1%. In 1991, this mosquito was no
longer captured.1 In 1995, despite heavy rains, its
populations did not recover because larval habitats were not
restored. In Niger, An funestus was also one of the main
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